STERIS plc financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data STERIS plc files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2017	FY2019	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
Revenue	2,613	2,620	2,782	3,031	3,108	4,223	4,536	5,139	5,460	5,936
Cost of revenue	1,587	1,527	1,607	1,711	1,764	2,340	2,556	2,921	3,057	3,309
Gross profit	1,026	1,093	1,175	1,320	1,343	1,883	1,981	2,218	2,403	2,627
Research and development	59.4	60.8	63	65.5	66.3	86.7	98.5	104	108	113
Selling, general and administrative	682	632	670	717	731	1,318	1,091	1,252	1,334	1,408
Operating expenses	800	693	764	783	795	1,405	1,190	1,382	1,536	1,525
Operating income	226	400	411	537	548	478	791	836	867	1,102
Interest expense	44.5	50.6	45	40.3	37.2	89.5	108	144	86.3	60.7
Other non-operating income	-41.6	-44.9	-42	-38.3	-30.8	-111	-111	-133	-70.4	-54.4
Pre-tax income	185	355	369	499	518	367	680	703	796	1,047
Income tax	74	63.4	64.3	90.9	121	82.3	124	150	185	262
Net income to minority interests	0.67	0.71	1.03	0.2	-0.53	-1.02	-1.22	1.8	1.4	2.8
Net income	110	291	304	408	397	244	107	378	615	782
EBITDA	414	578	637	734	768	1,031	1,344	1,401	1,343	1,588
EPS, basic	1.29	3.42	3.59	4.81	4.66	2.50	1.07	3.83	6.24	7.97
EPS, diluted	1.28	3.39	3.55	4.76	4.63	2.48	1.07	3.81	6.20	7.93
Shares, basic (weighted)	85.5	85	84.6	84.8	85.2	97.5	99.7	98.8	98.6	98.2
Shares, diluted (weighted)	86.1	85.7	85.5	85.6	85.9	98.3	100	99.4	99.1	98.7
Dividend per share	1.09	1.21	1.33	1.45	1.57	1.69	1.84	2.03	2.23	2.46

Balance sheet

	FY2017	FY2019	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
Cash and equivalents	283	202	221	320	221	348	208	207	172	440
Receivables		528	565	586	609	799	865	1,008	1,044	1,093
Inventory		206	208	264	315	575	604	675	581	632
Total current assets		990	1,054	1,224	1,212	1,879	2,011	2,869	2,001	2,395
Property, plant and equipment		1,011	1,032	1,112	1,235	1,553	1,633	1,765	1,957	2,161
Lease right-of-use assets			0	132	150	188	167	173	156	155
Goodwill	2,231	2,434	2,323	2,356	3,026	3,939	3,879	4,071	4,096	4,195
Intangible assets		727	605	565	898	3,329	2,077	2,119	1,854	1,620
Other non-current assets		39.4	60.2	51.6	52.7	70.7	77.9	66.2	83	211
Total assets		5,200	5,073	5,441	6,574	11,424	10,822	11,064	10,147	10,737
Accounts payable		136	153	149	157	226	264	252	281	339
Accrued liabilities		168	188	192	221	307	298	320	368	402
Short-term debt				0	0	143	60	85.9	125	119
Total current liabilities		398	465	504	578	922	862	931	1,022	1,145
Long-term debt		1,316	1,183	1,151	1,651	2,945	3,019	3,120	1,919	1,813
Lease liabilities					130	155	140	146	125	120
Other non-current liabilities		109	87.8	90.3	88	75.6	76.1	71.5	61.9	71.7
Total liabilities		1,983	1,887	2,023	2,683	4,879	4,735	4,748	3,531	3,540
Total debt		1,316	1,183	1,151	1,651	2,945	3,019	3,120	1,919	1,813
Retained earnings		1,146	1,339	1,659	1,939	1,999	1,912	2,088	2,475	3,016
Other comprehensive income	-241	11.7	-160	-235	-61.2	-210	-321	-329	-292	-113
Shareholders' equity		3,206	3,178	3,405	3,881	6,532	6,077	6,302	6,603	7,184
Minority interests		11.3	7.99	12.8	10.5	12.3	9.97	13.2	12.4	13.6
Total equity	2,810	3,217	3,197	3,418	3,891	6,545	6,087	6,315	6,616	7,197
Total liabilities and equity		5,200	5,073	5,441	6,574	11,424	10,822	11,064	10,147	10,737
Shares outstanding		84.7	84.5	84.9	85.4	100	98.6	98.9	98.3	97.8

Cash flow statement

	FY2017	FY2019	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
Net income	111	292	305	408	397	243	106	380	616	785
Depreciation and amortization	188	178	226	197	219	553	553	565	476	487
Stock-based compensation	18.8	22.2	24	23.8	26	57.7	39	56.5	57.4	61.7
Deferred income tax	31.3	-24.7	-6.62	9.44	4.24	-107	-186	-131	-76.5	-16.9
Change in receivables	-48.1	-37.7	-48.5	-17.9	12.1	-52	-133	-128	-28.8	-25.1
Change in inventory	-12.8	-5.18	-14.2	-39.1	3.77	-103	-124	-37.5	73.1	-24
Change in payables	6.88	0.56	21.2	-2.78	-7.21	14.9	53.3	-19	33.6	51.1
Cash from operations	424	458	540	591	690	685	757	973	1,148	1,341
Capital expenditures	-173	-165	-190	-215	-239	-288	-362	-360	-370	-369
Acquisitions	-65.6	-46.3	-13.3	-110	-909	-550	-42.6	-546	-54.1	-20.1
Purchases of investments	-6.36	0	-4.96	0	-4.4	0	0	-1.5	-10.8	-134
Cash from investing	-104	-204	-213	-320	-1,154	-667	-383	-887	389	-513
Debt issued			0	0	550	650	0	0
Debt repaid	-173	-223	-85	0	-35
Stock issued	4.96	11.1	13.3	34.7	26.7	10.1	1.83	10.5	25.5	32.9
Share buybacks	-97.5	-65.5	-81.5	-51.2	-14.6	-55.8	-309	-11.8	-211	-236
Dividends paid	-93.2	-103	-113	-123	-134	-163	-183	-201	-220	-242
Cash from financing	-267	-356	-295	-163	346	116	-499	-85.2	-1,572	-568
Exchange rate effect	-18.7	21	-12.4	-8.73	19.8	-6.29	-14.9	-2.1	0.2	7.2
Net change in cash	34.1	-81.4	19.1	98.9	-99.1	128	-140	-1.3	-35.3	268
Free cash flow	251	292	350	376	450	397	395	613	778	972
Interest paid	42.8	48.7	44.1	38	36.3	84.7	108	142	89.4	64.7
Income taxes paid	78	85.6	64.7	92.5	110	138	255	271	274	289

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $208.93 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	44.4%	Gross profit / revenue.
Operating margin	18.9%	Operating income / revenue.
EBITDA margin	27.0%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	18.0%	Pre-tax income / revenue.
Net margin	13.3%	Net income / revenue.
FCF margin	15.3%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	21.3%	Cash from operations / revenue.
Effective tax rate	25.8%	Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)	11.2%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	7.5%	Net income / average total assets.
Return on invested capital (ROIC)	10.1%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue	1.9%	Research and development expense / revenue.
SG&A / revenue	23.6%	Selling, general and administrative expense / revenue.
Stock-based pay / revenue	1.0%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	6.0%	Capital expenditures / revenue.
D&A / revenue	8.1%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	8.7%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	9.4%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	13.8%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	9.3%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	9.9%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	14.4%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating income growth, 1y	27.1%	Operating income vs the same period a year earlier. Only from a positive base.
Operating income CAGR, 3y	11.7%	Compound annual growth of operating income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating income CAGR, 5y	15.0%	Compound annual growth of operating income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EBITDA growth, 1y	18.3%	EBITDA vs the same period a year earlier. Only from a positive base.
EBITDA CAGR, 3y	5.7%	Compound annual growth of ebitda over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EBITDA CAGR, 5y	15.7%	Compound annual growth of ebitda over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Net income growth, 1y	27.3%	Net income vs the same period a year earlier. Only from a positive base.
Net income CAGR, 3y	94.1%	Compound annual growth of net income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Net income CAGR, 5y	14.5%	Compound annual growth of net income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EPS growth, 1y	27.9%	EPS vs the same period a year earlier. Only from a positive base.
EPS CAGR, 3y	95.0%	Compound annual growth of eps over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EPS CAGR, 5y	11.4%	Compound annual growth of eps over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y	16.8%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y	21.0%	Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow CAGR, 5y	14.2%	Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Free cash flow growth, 1y	25.0%	Free cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow CAGR, 3y	35.0%	Compound annual growth of free cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Free cash flow CAGR, 5y	16.6%	Compound annual growth of free cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Dividend per share growth, 1y	10.3%	Dividend per share vs the same period a year earlier. Only from a positive base.
Dividend per share CAGR, 3y	10.2%	Compound annual growth of dividend per share over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Dividend per share CAGR, 5y	9.4%	Compound annual growth of dividend per share over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y	8.8%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	5.7%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	13.1%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	5.8%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	-0.3%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	10.3%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	-0.4%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	-0.5%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	2.8%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	1.91x	Current assets / current liabilities.
Quick ratio	1.17x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.38x	(Cash + short-term investments) / current liabilities.
Debt / equity	0.23x	Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets	15.4%	Total debt / total assets.
Liabilities / assets	32.7%	Total liabilities / total assets.
Net debt	$1.17B	Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA	0.72x	Net debt / EBITDA (twelve months), when EBITDA is positive.
Interest coverage	18.8x	Operating income / interest expense.
Working capital	$1.16B	Current assets - current liabilities.
Goodwill and intangibles / assets	53.6%	(Goodwill + intangible assets) / total assets.
Tangible book value	$1.45B	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.56x	Revenue / average total assets.
Fixed asset turnover	2.78x	Revenue / average property, plant and equipment.
Receivables turnover	5.96x	Revenue / average receivables.
Days sales outstanding	61 days	365 x average receivables / revenue.
FCF conversion	115.0%	Free cash flow / net income, when net income is positive.
Capex / operating cash flow	28.2%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	$8.22	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$61.67	Revenue / diluted weighted shares.
FCF per share	$9.45	Free cash flow / diluted weighted shares.
Operating cash flow per share	$13.16	Cash from operations / diluted weighted shares.
Book value per share	$73.91	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$14.91	Tangible book value / shares outstanding.
Cash per share	$4.95	(Cash + short-term investments) / shares outstanding.
Payout ratio	30.7%	Dividends paid / net income, when net income is positive.
Dividends / FCF	26.7%	Dividends paid / free cash flow, when free cash flow is positive.
Buybacks / FCF	36.8%	Share buybacks / free cash flow, when free cash flow is positive.

Valuation

Metric	Value	How it is calculated
Market cap	$20.37B	Share price x shares outstanding.
Enterprise value	$21.54B	Market cap + total debt - cash - short-term investments.
P/E	25.3x	Market cap / net income. Only when net income is positive.
P/S	3.37x	Market cap / revenue.
P/B	2.83x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	14.0x	Market cap / tangible book value, when positive.
P/FCF	22.0x	Market cap / free cash flow. Only when free cash flow is positive.
P/OCF	15.8x	Market cap / cash from operations, when positive.
EV/Sales	3.57x	Enterprise value / revenue.
EV/EBIT	18.9x	Enterprise value / operating income, when both are positive.
EV/EBITDA	13.2x	Enterprise value / EBITDA, when both are positive.
EV/FCF	23.3x	Enterprise value / free cash flow, when both are positive.
FCF yield	4.5%	Free cash flow / market cap.
Earnings yield	4.0%	Net income / market cap (the inverse of P/E).
Dividend yield	1.2%	Dividends paid over the period / market cap.
Shareholder yield	2.9%	(Dividends paid + share buybacks) / market cap.
PEG	0.27x	P/E / EPS growth per year over 3 years (in percent). Only when both are positive.

What was STERIS plc's revenue in fiscal 2026?

STERIS plc reported revenue of $5.94B for fiscal 2026, 8.7% higher than the year before.

Was STERIS plc profitable in fiscal 2026?

Yes. Net income was $782.3M, a net margin of 13.2%.

How much free cash flow did STERIS plc generate in fiscal 2026?

Cash from operations of $1.34B minus capital expenditures of $369.0M left free cash flow of $972.4M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to STERIS plc